(Date:11/24/2009)... The molecular cause of i...research will be presented at the upcoming 2009 Ad...squo;s & Colitis Foundation’s Clinical &...d, Florida, that may identify a causative mutation... New York, NY (Vocus) November 24, 2009 -- The...
(Date:11/24/2009)...,, PITTSBURGH,Nov.24/PRNewswire/--Whilethehol...elebrate,thistimeoftheyearcanbedifficultforthosegr...isdifficultforchildrenandfamilies.Theholidayseason... ,, TheHighmarkCaringPlace,ACenterforGrievingCh...hosewhoneedsupport.Inadditiontohavingavarietyofpri...
(Date:11/24/2009)...,, BIRMINGHAM,Ala.,Nov.24/PRNewswire-FirstCal...editwillparticipateintheBankofAmericaMerrillLynch2...HealthSouthSeniorVicePresidentandTreasurerEdFaywil...resentationwillbewebcastliveandwillbeavailableat h...ablelink. ,, AboutHealthSouth ,, HealthSou...
(Date:11/24/2009)...In-hospital death rates didn,t differ greatly betw... , TUESDAY, Nov. 24 (HealthDay News) -- Do ...ssarily produce the best results for patients? May...actice makes perfect" when it comes to artery-open...000 patients finds low- and high-volume hospitals ...
(Date:11/24/2009)...,, BELGRADE,Serbia,Nov.24/PRNewswire-FirstCal...l.com/ )anditsoperatingsubsidiarySlavicaBioChem,is...ers.HTDSmanagementcontinuesduediligencewiththeEUst...previousannouncementonoraboutOct29,2009whichthecom...te.jsp?symbol=HTDS#getNews . ,, HTDSandSlavicaB...
Breaking Medicine News(10 mins):Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 2Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 3Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 4Health News:Highmark Caring Place Resources Help Children and Families Who Are Grieving During the Holidays 2Health News:Angioplasty Outcomes May Vary Little Between Hospitals 2Health News:Angioplasty Outcomes May Vary Little Between Hospitals 3Health News:Hard To Treat Diseases (HTDS) Exploration Of A 25 Billion Dollar Industry Regenerative Medicine and Stem Cell Bank Targeted Merger 2Health News:Hard To Treat Diseases (HTDS) Exploration Of A 25 Billion Dollar Industry Regenerative Medicine and Stem Cell Bank Targeted Merger 3...nd Drug Administration has cleared DizzyFIX, an at...lps guide patients through the Epley maneuver, for...ry, Canada (PRWEB) September 23, 2008 -- The U.S. ...helps guide patients through the Epley maneuver, f...
...ed study conducted in the U.S., demonstrated both...dren with nasal symptoms associated with perenn...3 Sanofi-aventis,announced today the U.S. Food an...symptoms associated with seasonal and,perennial al...
...,Healthcare REIT, Inc. today announced the acquisi...g two medical office buildings in Oklahoma,City. L... are situated on,the Deaconess Hospital campus., ... Healthcare REIT portfolio," said Danny Prosky, Ex...
...rs,of Congress on September 19, Cardinal Justin Ri...edom of Choice Act" or "FOCA" (S. 1173, H.R.,1964)... would deprive the,American people in all 50 state...nd promoting abortion with their tax,dollars. And ...
...hcare, Inc., a leader in the field of kidney disea...pients of its 2008 Norman S. Coplon Extramural Gra...cientists at leading universities and medical cent...usiness Wire EON) September 22, 2008 -- These gra...
...nger , , MONDAY, Sept. 22 (HealthDay News)...eat people who have an underactive thyroid gland t...e worry, researchers report. , As many as 27 milli...iagnosed. , "At this point, how to manage older pe...
Other Medicine News:Health News:Clearwater's Canadian at-Home Dizziness Treatment Device Cleared by FDA 2Health News:FDA Approves Nasacort AQ(R) Nasal Spray for Children Aged 2-5 years old 2Health News:FDA Approves Nasacort AQ(R) Nasal Spray for Children Aged 2-5 years old 3Health News:FDA Approves Nasacort AQ(R) Nasal Spray for Children Aged 2-5 years old 4Health News:Grubb & Ellis Healthcare REIT Acquires Oklahoma City Medical Portfolio 2Health News:Grubb & Ellis Healthcare REIT Acquires Oklahoma City Medical Portfolio 3Health News:Pro-Life Chair to Congress: 'We Can't Reduce Abortions By Promoting Abortion' 2Health News: Satellite Healthcare Announces 2008 Norman S. Coplon Extramural Grants : Grants Foster Next-Generation Kidney Disease Researchers 2Health News: Satellite Healthcare Announces 2008 Norman S. Coplon Extramural Grants : Grants Foster Next-Generation Kidney Disease Researchers 3Health News:Low Thyroid Function Linked to Heart Failure Risk 2Health News:Low Thyroid Function Linked to Heart Failure Risk 3(Date:11/24/2009)..., MOUNTAINVIEW,Calif.,Nov.24/PRNewswire/--Satellit...rsofkidneydialysisservicesandamajorsponsorofnephro...seasesurvivorandchefEliasNasrallahinhisefforttosup..., EliasNasrallahbuiltasuccessfulcareerasacheffort...wnfiveyearsago,whenhewasdiagnosedwithEndStageRenal...
(Date:11/24/2009)..., SANDIEGO,Nov.24/PRNewswire-FirstCall/--Orexigen&...uticalcompanyfocusedonthetreatmentofobesity,todaya...teeoftheCompany,sBoardofDirectorsgrantedaninduceme...oPrestonKlassen,M.D.,itsnewlyappointedHeadoftheGlo...tobeanincentivestockoptiontotheextentpermittedbyla...
(Date:11/24/2009)..., NEWYORK,Nov.24/PRNewswire-FirstCall/--KeryxBioph...tRonBentsur,theCompany,sChiefExecutiveOfficer,issc...areConferencebeingheldinNewYorkCity. ,, Mr.Bent...mber2ndat10:30AMETandwillbeaccessiblefromtheInvest...vestors.keryx.com .Anarchivedversionofthewebcastwi...
Breaking Medicine Technology:Satellite Healthcare and Renal Disease Survivor Elias Nasrallah Join Forces to Support the Homeless This Holiday Season 2Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 2Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 3Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2BellaDerm 28TM 29 a Unique Human Skin Tissue Implant for Facial and Body Contouring is Introduced by MTF 48423 1BellaDerm 28TM 29 a Unique Human Skin Tissue Implant for Facial and Body Contouring is Introduced by MTF 48423 2MonoSol Rx Announces FDA Acceptance of NDA for Ondansetron Orally Dissolving Film Strip 48421 1MonoSol Rx Announces FDA Acceptance of NDA for Ondansetron Orally Dissolving Film Strip 48421 2MonoSol Rx Announces FDA Acceptance of NDA for Ondansetron Orally Dissolving Film Strip 48421 3Strativas New Drug Application for Ondansetron Orally Dissolving Film Strip Accepted by FDA 12557 1Strativas New Drug Application for Ondansetron Orally Dissolving Film Strip Accepted by FDA 12557 2Strativas New Drug Application for Ondansetron Orally Dissolving Film Strip Accepted by FDA 12557 3...y Reduces Postop Pain, Opioid Use, and Reduces Opi...rd Pain Medication , , PARSIPPANY, N.J., Dec...intraoperative administration of EXPAREL(TM) (Depo...arthroplasty, or TKA, showed that the novel, susta...rolled moderate-to-severe postoperative pain for o...
... Inc.,(Nasdaq: OREX ) today announced changes to...s on its late-stage obesity programs and realign i...se changes are as follows: , -- The explora...(zonisamide and olanzapine to mitigate antipsychot...e and naltrexone to reduce symptoms of obsessive-,...
Other Medicine Technology:Positive Phase II Study of Pacira's EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress 2Positive Phase II Study of Pacira's EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress 3Positive Phase II Study of Pacira's EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress 4Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team 2Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team 3...nd vertical gel electrophoresis applications. Low ...d. In this power supply model, output is controlle...tage. Four sets of output terminals allow four app...supply's light, compact and stackable design saves...
e-power Power Supply
PowerEase® 500 Power Supply (220/240 VAC 50/60 Hz)
Power Supply EV265 for electrophoresis, 230V
Medicine Products: